Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,085
archived clinical trials in
Cervical Cancer

Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers
Status: Enrolling
Updated:  9/10/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers
Status: Enrolling
Updated: 9/10/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy Study of Vaginal Mesh for Prolapse
A Randomized Clinical Trial of Vaginal Mesh for Prolapse
Status: Enrolling
Updated:  9/21/2015
MedStar Washington Hospital Center
mi
from
Washington,
Efficacy Study of Vaginal Mesh for Prolapse
A Randomized Clinical Trial of Vaginal Mesh for Prolapse
Status: Enrolling
Updated: 9/21/2015
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Efficacy Study of Vaginal Mesh for Anterior Prolapse
A Randomized Clinical Trial of Vaginal Mesh for Anterior Prolapse
Status: Enrolling
Updated:  9/21/2015
Wahington Hospital Center
mi
from
Washington,
Efficacy Study of Vaginal Mesh for Anterior Prolapse
A Randomized Clinical Trial of Vaginal Mesh for Anterior Prolapse
Status: Enrolling
Updated: 9/21/2015
Wahington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening
Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening
Status: Enrolling
Updated:  9/23/2015
Michigan State University
mi
from
East Lansing, MI
Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening
Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening
Status: Enrolling
Updated: 9/23/2015
Michigan State University
mi
from
East Lansing, MI
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Bismarck, ND
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Bismarck, ND
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Tucson, AZ
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Sacramento, CA
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Orlando, FL
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Tampa, FL
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
St. Louis Park, MN
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
St. Louis Park, MN
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Winston Salem, NC
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Winston Salem, NC
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Columbus, OH
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Philadelphia, PA
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Research Site
mi
from
Adelaide,
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Research Site
mi
from
Adelaide,
Click here to add this to my saved trials
ANTI-TAC THERAPY FOR UVEITIS
Trial of Treatment of Non-Infectious Intermediate and Posterior Uveitis With Humanized Anti-Tac Antibody Therapy
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
ANTI-TAC THERAPY FOR UVEITIS
Trial of Treatment of Non-Infectious Intermediate and Posterior Uveitis With Humanized Anti-Tac Antibody Therapy
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Screening for NEI Clinical Studies
Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Ocular Inflammatory or Immunologic Diseases
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Screening for NEI Clinical Studies
Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Ocular Inflammatory or Immunologic Diseases
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
Daclizumab for Active, Non-infectious, Sight-threatening Uveitis: A Phase II Pilot Study
Status: Enrolling
Updated:  9/26/2015
National Eye Institute (NEI)
mi
from
Bethesda, MD
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
Daclizumab for Active, Non-infectious, Sight-threatening Uveitis: A Phase II Pilot Study
Status: Enrolling
Updated: 9/26/2015
National Eye Institute (NEI)
mi
from
Bethesda, MD
Click here to add this to my saved trials
Daclizumab and Sirolimus to Treat Uveitis
Combination Daclizumab/Sirolimus Therapy For the Induction of Immune Tolerance in Non-Infectious Intermediate and Posterior Uveitis
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Daclizumab and Sirolimus to Treat Uveitis
Combination Daclizumab/Sirolimus Therapy For the Induction of Immune Tolerance in Non-Infectious Intermediate and Posterior Uveitis
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Immune Indicators of Uveitis
Use of Immune Cell Markers, Cytokines, Transcription Factors and Surface CD Markers as Markers of Ocular Inflammatory Activity
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Immune Indicators of Uveitis
Use of Immune Cell Markers, Cytokines, Transcription Factors and Surface CD Markers as Markers of Ocular Inflammatory Activity
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated:  9/26/2015
Johns Hopkins University
mi
from
Baltimore, MD
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated: 9/26/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated:  9/26/2015
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated: 9/26/2015
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Click here to add this to my saved trials
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated:  9/26/2015
Oregon Health and Sciences University
mi
from
Portland, OR
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated: 9/26/2015
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Differences in Genes and Proteins in Active and Controlled Uveitis
Analysis of Differential Gene Expression Profiles in Patients With Defined Ocular Inflammatory Diseases Using CDNA Microarrays and Proteomics
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Differences in Genes and Proteins in Active and Controlled Uveitis
Analysis of Differential Gene Expression Profiles in Patients With Defined Ocular Inflammatory Diseases Using CDNA Microarrays and Proteomics
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Eye and Immunogenetic Features of Sarcoidosis
Ocular and Immuno-Genetic Manifestations of Sarcoidosis
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Eye and Immunogenetic Features of Sarcoidosis
Ocular and Immuno-Genetic Manifestations of Sarcoidosis
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma
The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma
The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Living With Cervical Cancer: Assessing Utilities Associated With Common Treatment Complications
Living With Cervical Cancer: Assessing Utilities Associated With Common Treatment Complications
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin-Madison
mi
from
Madison, WI
Living With Cervical Cancer: Assessing Utilities Associated With Common Treatment Complications
Living With Cervical Cancer: Assessing Utilities Associated With Common Treatment Complications
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Preservation of Ovarian Function Via LOT in Squamous Cell Carcinoma of the Cervix
Preservation of Ovarian Function Via Laparoscopic Transposition in Patients With Locally Advanced Squamous Cell Carcinoma of the Cervix
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin
mi
from
Madison, WI
Preservation of Ovarian Function Via LOT in Squamous Cell Carcinoma of the Cervix
Preservation of Ovarian Function Via Laparoscopic Transposition in Patients With Locally Advanced Squamous Cell Carcinoma of the Cervix
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Laparoscopic Sentinel Lymph Node Localization in Operable Cervix Cancer
Laparoscopic Sentinel Lymph Node Localization in Patients With Operable Cervical Cancer - A Pilot Study
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin
mi
from
Madison, WI
Laparoscopic Sentinel Lymph Node Localization in Operable Cervix Cancer
Laparoscopic Sentinel Lymph Node Localization in Patients With Operable Cervical Cancer - A Pilot Study
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Disseminated Endometrial Cancer Cells During Sonohysterography
The Incidence of Disseminated Endometrial Cancer Cells During Sonohysterography and Their Functional Viability: a Prospective Study
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin
mi
from
Madison, WI
Disseminated Endometrial Cancer Cells During Sonohysterography
The Incidence of Disseminated Endometrial Cancer Cells During Sonohysterography and Their Functional Viability: a Prospective Study
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Sexual Functioning in Endometrial Cancer
Sexual Functioning in Endometrial Cancer Survivors
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin School of Medicine and Public Health
mi
from
Madison, WI
Sexual Functioning in Endometrial Cancer
Sexual Functioning in Endometrial Cancer Survivors
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin School of Medicine and Public Health
mi
from
Madison, WI
Click here to add this to my saved trials
Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients
Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Endometrial Cancer Patients
Status: Enrolling
Updated:  10/1/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients
Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Endometrial Cancer Patients
Status: Enrolling
Updated: 10/1/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters
Status: Enrolling
Updated:  10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters
Status: Enrolling
Updated: 10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Geauga Regional Hospital
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Geauga Regional Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Lake/University Ireland Cancer Center
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Lake/University Ireland Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
University Suburban Health Center
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
University Suburban Health Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
UHHS Chagrin Highlands Medical Center
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
UHHS Chagrin Highlands Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Southwest General Health Center
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Southwest General Health Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
UHHS Westlake Medical Center
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
UHHS Westlake Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated:  10/1/2015
Mercy Cancer Center at Mercy Medical Center
mi
from
Cleveland, OH
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers
Status: Enrolling
Updated: 10/1/2015
Mercy Cancer Center at Mercy Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated:  10/5/2015
Novartis Investigative Site
mi
from
Beverly Hills, CA
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated: 10/5/2015
Novartis Investigative Site
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated:  10/5/2015
Novartis Investigative Site
mi
from
Cambridge, MA
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated: 10/5/2015
Novartis Investigative Site
mi
from
Cambridge, MA
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated:  10/5/2015
Novartis Investigative Site
mi
from
Slingerlands, NY
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated: 10/5/2015
Novartis Investigative Site
mi
from
Slingerlands, NY
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated:  10/5/2015
Novartis Investigative Site
mi
from
Arlington, TX
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated: 10/5/2015
Novartis Investigative Site
mi
from
Arlington, TX
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated:  10/5/2015
Novartis Investigative Site
mi
from
Houston, TX
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated: 10/5/2015
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated:  10/5/2015
Novartis Investigative Site
mi
from
London,
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated: 10/5/2015
Novartis Investigative Site
mi
from
London,
Click here to add this to my saved trials
Folic Acid Clinical Trial for the Prevention of Cervical Cancer
HPV Clearance by Folic Acid Supplementation (FACT for HPV)
Status: Enrolling
Updated:  10/6/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Folic Acid Clinical Trial for the Prevention of Cervical Cancer
HPV Clearance by Folic Acid Supplementation (FACT for HPV)
Status: Enrolling
Updated: 10/6/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Status: Enrolling
Updated:  10/8/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Status: Enrolling
Updated: 10/8/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence
Status: Enrolling
Updated:  10/8/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence
Status: Enrolling
Updated: 10/8/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials